The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs

Canadian Journal of Cardiology

Volumn 26, Issue 4, 2010, Pages 185-202

  Howlett, Jonathan G ^a   McKelvie, Robert S ^b   Costigan, Jeannine ^c   Ducharme, Anique ^d   Estrella Holder, Estrellita ^e   Ezekowitz, Justin A ^f   Giannetti, Nadia ^g   Haddad, Haissam ^h   Heckman, George A ^b,i   Herd, Anthony M ^j   Isaac, Debra ^a   Kouz, Simon ^k   Leblanc, Kori ^l   Liu, Peter ^l   Mann, Elizabeth ^m   Moe, Gordon W ⁿ   O'Meara, Eileen ^d   Rajda, Miroslav ^m   Siu, Samuel ^o   Stolee, Paul ⁱ   Swiggum, Elizabeth ^p   Zeiroth, Shelley ^j   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c St Mary's General Hospital   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e ST BONIFACE GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

ⁱ UNIVERSITY OF WATERLOO   (Canada)

^j UNIVERSITY OF MANITOBA   (Canada)

^k Centre Hospitalier Regional de Lanaudiere   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

ⁿ ST MICHAEL'S HOSPITAL   (Canada)

^o UNIVERSITY OF WESTERN ONTARIO   (Canada)

^p UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

Cardiomyopathy; Disease management; Ethnicity; Heart failure clinic; HF; Minority; Outcomes; Performance indicator; Peripartum; Pregnancy; Quality assurance; Quality of care

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; ETHNIC GROUP; HEALTH CARE SYSTEM; HEART FAILURE; HEMODYNAMICS; HUMAN; MEDICAL SOCIETY; MINORITY GROUP; PRACTICE GUIDELINE; PREGNANCY; PROGNOSIS; QUALITY CONTROL;

EID: 77950617490     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)70367-6     Document Type: Article

References (196)

1. Statistics Canada. Canada's ethnocultural mosaic in 2006. 2006 Census of Canada, 2008
2. Rideout E, Montemuro M. Hope, morale and adaptation in patients with chronic HF. J Adv Nurs 1986;11:429-438
3. Mendez GF, Cowie MR. The epidemiological features of HF in developing countries: A review of the literature. Int J Cardiol 2001;80:213-219 (Pubitemid 32905414)
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-952 (Pubitemid 39208455)
5. Krauser DG, Chen AA, Tung R, Anwaruddin S, Baggish AL, Januzzi JL Jr. Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 2006;12:452-457 (Pubitemid 46106983)
6. Ajayi AA, Balogun MO, Oyewo EA, Ladipo GO. Enalapril in African patients with congestive cardiac failure. Br J Clin Pharmacol 1989;27:400-403 (Pubitemid 19097454)
7. Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in HF: A comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-1528
8. Balarajan R. Ethnicity and health: The challenges ahead. Ethn Health 1996;1:3-5.
9. Wild S, McKeigue P. Cross sectional analysis of mortality by country of birth in England and Wales, 1970-1992. BMJ 1997;314:705-710 (Pubitemid 27113071)
10. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000;356:279-284 (Pubitemid 30459585)
11. Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: An analysis of 1.2 million deaths. CMAJ 1999;161:132-138 (Pubitemid 29375967)
12. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J Hypertens 2004;22:11-19 (Pubitemid 38293521)
13. Ueshima H, Zhang XH, Choudhury SR. Epidemiology of hypertension in China and Japan. J Hum Hypertens 2000;14:765-769
14. Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly admitted to hospital with HF in the United Kingdom: Historical cohort study. BMJ 2003;327:526-531 (Pubitemid 37088496)
15. Newton JD, Blackledge HM, Squire IB. Ethnicity and variation in prognosis for patients newly hospitalised for HF: A matched historical cohort study. Heart 2005;91:1545-1550
16. Singh N, Gupta M. Clinical characteristics of South Asian patients hospitalized with HF. Ethn Dis 2005;15:615-619 (Pubitemid 41645128)
17. Chow CM, Chu JY, Tu JV, Moe GW. Lack of awareness of heart disease and stroke among Chinese Canadians: Results of a pilot study of the Chinese Canadian Cardiovascular Health Project. Can J Cardiol 2008;24:623-628
18. Mendez GF, Cowie MR. The epidemiological features of HF in developing countries: A review of the literature. Int J Cardiol 2001;80:213-219 (Pubitemid 32905414)
19. Sanderson JE, Tse TF. HF: A global disease requiring a global response. Heart 2003;89:585-586
20. Sanderson JE, Chan SK, Chan WW, Hung YT, Woo KS. The aetiology of HF in the Chinese population of Hong Kong - a prospective study of 730 consecutive patients. Int J Cardiol 1995;51:29-35.
21. Yip GW, Ho PP, Woo KS, Sanderson JE. Comparison of frequencies of left ventricular systolic and diastolic HF in Chinese living in Hong Kong. Am J Cardiol 1999;84:563-567
22. Tso DK, Moe G. Cardiovascular disease in Chinese Canadians: A case-mix study from an urban tertiary care cardiology clinic. Can J Cardiol 2002;18:861-869
23. Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398-1405 (Pubitemid 40523734)
24. Jiang H, Ge J. Epidemiology and clinical management of cardiomyopathies and HF in China. Heart 2009;95:1727-1731
25. Yip GW, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: A randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in HF with a normal ejection fraction. Heart 2008;94:573-580
26. Chan WK, Chan TY, Luk WK, Leung VK, Li TH, Critchley JA. A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1993;44:299-300.
27. Woo J, Chan TY. A high incidence of cough associated with combination therapy of hypertension with isradipine and lisinopril in Chinese subjects. Br J Clin Pract 1991;45:178-180
28. Statistics Canada. 2001 Census: Ethnocultural Portrait. Ottawa: Statistics Canada, 2005.
29. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J. Effects of an angiotensin-converting enzyme inhibitor- based regimen on pneumonia risk. Am J Respir Crit Care Med 2004;169:1041-1045 (Pubitemid 38543644)
30. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989;320:565-570
31. Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. [Guidelines for the diagnosis and management of chronic HF.] Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:1076-1095
32. Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-2211
33. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic HF in the Adult - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of HF): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005;112:1825-1852
34. Yancy CW. HF in African Americans: A cardiovascular engima. J Card Fail 2000;6:183-186
35. Afzal A, Ananthasubramaniam K, Sharma N, et al. Racial differences in patients with HF. Clin Cardiol 1999;22:791-794
36. Bibbins-Domingo K, Pletcher MJ, Lin F, et al. Racial differences in incident heart failure among young adults. N Engl J Med 2009;360:1179-1190
37. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-616 (Pubitemid 29093720)
38. Alexander M, Grumbach K, Selby J, Brown AF, Washington E. Hospitalization for congestive HF. Explaining racial differences. JAMA 1995;274:1037-1042
39. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of HF. Traits among urban Blacks. Arch Intern Med 1988;148:2013-2016
40. Saunders E. Hypertension in minorities: Blacks. Am J Hypertens 1995;8:115s-119s.
41. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-1357
42. A trial of the beta-blocker bucindolol in patients with advanced chronic HF. N Engl J Med 2001;344:1659-1667 (Pubitemid 32479963)
43. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic HF. N Engl J Med 2001;344:1358-1365
44. Goldstein S, Deedwania P, Gottlieb S, Wikstrand J. Metoprolol CR/XL in black patients with HF (from the Metoprolol CR/XL randomized intervention trial in chronic HF). Am J Cardiol 2003;92:478-480 (Pubitemid 36959893)
45. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497 (Pubitemid 28384881)
46. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for HF: Analysis of the vasodilator-HF trials. Vasodilator-HF Trial Study Group. J Card Fail 1999;5:178-187 (Pubitemid 29449255)
47. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in Blacks with HF. N Engl J Med 2004;351:2049-2057 (Pubitemid 39482498)
48. Newbold KB. Problems in search of solutions: Health and Canadian aboriginals. J Community Health 1998;23:59-73. (Pubitemid 28127954)
49. Anand SS, Yusuf S, Jacobs R, et al. Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: The Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). Lancet 2001;358:1147-1153 (Pubitemid 32971848)
50. Shah BR, Hux JE, Zinman B. Increasing rates of ischemic heart disease in the native population of Ontario, Canada. Arch Intern Med 2000;160:1862-1866 (Pubitemid 30418826)
51. Burrows NR, Geiss LS, Engelgau MM, Acton KJ. Prevalence of diabetes among Native Americans and Alaska Natives, 1990-1997: An increasing burden. Diabetes Care 2000;23:1786-1790
52. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective. J Pediatr 2000;136:664-672 (Pubitemid 30318399)
53. Tonelli M, Hemmelgarn B, Manns B, et al. Death and renal transplantation among Aboriginal people undergoing dialysis. CMAJ 2004;171:577-582 (Pubitemid 39273932)
54. Australian Institute of Health and Welfare. Cardiovascular disease and its associated risk factors in Aboriginal and Torres Strait Islander peoples 2004-2005. Cardiovascular Disease Series Number 29. 〈www.aihw.gov.au/ publications/index.cfm/title/10549〉 (Accessed on June 18, 2009).
55. Macaulay AC. Improving aboriginal health: How can health care professionals contribute? Can Fam Physician 2009;55:334-339
56. Hoy WE, Kondalsamy-Chennakesavan S, Scheppingen J, Sharma S, Katz I. A chronic disease outreach program for Aboriginal communities. Kidney Int Suppl 2005;S76-S82. (Pubitemid 43307854)
57. Hunter S, Robson SC. Adaptation of the maternal heart in pregnancy. Br Heart J 1992;68:540-543 (Pubitemid 23001727)
58. Crapo R. Normal cardiopulmonary physiology during pregnancy. Clin Obstet Gynecol 1996;39:3-16. (Pubitemid 26060211)
59. Clark SL, Cotton DB, Lee W, et al. Central hemodynamic assessment of normal term pregnancy. Am J Obstet Gynecol 1989;161:1439-1442 (Pubitemid 20024006)
60. Capeless EL, Clapp JF. Cardiovascular changes in early phase of pregnancy. Am J Obstet Gynecol 1989;161:1449-1453 (Pubitemid 20024008)
61. Lee W. Cardiorespiratory alterations during normal pregnancy. Crit Care Clin 1991;7:763-775
62. Duvekot JJ, Cheriex EC, Pieters FA, et al. Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol 1993;169:1382.
63. Gant NF, Worley RJ, Everett R, MacDonald PC. Control of vascular responsiveness during human pregnancy. Kidney Int 1980;18:253. (Pubitemid 11194099)
64. Kametas NA, McAuliffe F, Krampl E, et al. Maternal cardiac function in twin pregnancy. Obstet Gynecol 2003;102:806. (Pubitemid 37206418)
65. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989;256:H1060.
66. Van Oppen AC, Stigter RH, Bruinse HW. Cardiac output in normal pregnancy: A critical review. Obstet Gynecol 1996;87:310.
67. Desai DK, Moodley J, Naidoo DP. Echocardiographic assessment of cardiovascular hemodynamics in normal pregnancy. Obstet Gynecol 2004;104:20. (Pubitemid 40458900)
68. Mabie WC, DiSessa TG, Crocker LG, et al. A longitudinal study of cardiac output in normal human pregnancy. Am J Obstet Gynecol 1994;170:849-856 (Pubitemid 24224713)
69. Kinsella SM, Lohmann G. Supine hypotensive syndrome. Obstet Gynecol 1994;83:774. (Pubitemid 24153478)
70. Avila WS, Rossi EG, Ramires JA. Pregnancy in patients with heart disease: Experience with 1000 cases. Clin Cardiol 2003;26:135-142 (Pubitemid 36330863)
71. Bernstein PS, Magriples U. Cardiomyopathy in pregnancy: A retrospective study. Am J Perinatol 2001;18:163-168 (Pubitemid 32587760)
72. Cutforth R, MacDonald CB. Heart sounds and murmurs in pregnancy. Am Heart J 1966;71:741.
73. Northcote RJ, Knight PV, Ballantyne D. Systolic murmurs in pregnancy: Value of echocardiographic assessment. Clin Cardiol 1985;8:327-328 (Pubitemid 15031536)
74. Oram S, Holt M. Innocent depression of the S-T segment and flattening of the T-wave during pregnancy. J Obstet Gynaecol Br Emp 1961;68:765.
75. Campos O, Andrade JL, Bocanegra J, et al. Physiologic multivalvular regurgitation during pregnancy: A longitudinal Doppler echocardiographic study. Int J Cardiol 1993;40:265. (Pubitemid 23256892)
76. Desai DK, Moodley J, Naidoo DP. Echocardiographic assessment of cardiovascular hemodynamics in normal pregnancy. Obstet Gynecol 2004;104:20. (Pubitemid 40458900)
77. Arnold MO, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendation on HF update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007;23:21-45. (Pubitemid 46403407)
78. Resnik JL, Hong C, Resnik R, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005;193:450. (Pubitemid 41159541)
79. Folk JJ, Lipari CW, Nosovitch JT, et al. Evaluating ventricular function with B-type natriuretic peptide in obstetric patients. J Reprod Med 2005;50:147.
80. McFaul PB, Dorman JC, Lamki H, et al. Pregnancy complicated by maternal heart disease: A review of 519 women. Br J Obstet Gynecol 1988:95;861-867
81. Siu S, Sermer M, Colman J, et al. Prospective multicentre study of pregnancy outcome in women with heart disease. Circulation 2001;104:515-521 (Pubitemid 32738118)
82. Sermer M, Colman J, Siu S. Pregnancy complicated by heart disease: A review of Canadian Experience. J Obstet Gynecol 2003;23:540-544 (Pubitemid 37188226)
83. Kovacs AH, Harrison JL, Colman JM, Sermer M, Siu SC, Silversides CK. Pregnancy and contraception in congenital heart disease: What women are not told. J Am Coll Cardiol 2008;52:577-578
84. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):844S-886S.
85. Heider AL, Kuller JA, Strauss RA, Wells SR. Peripartum cardiomyopathy: A review of the literature. Obstet Gynecol Surv 1999;45:526-531
86. Sharrock NE, Bading B, Mineo R, Blumenfeld JD. Deliberate hypotensive epidural anaesthesia for patients with normal and low cardiac output. Anesth Analg 1994;79:899-904. (Pubitemid 24324668)
87. George LM, Gatt SP, Lowe S. Peripartum cardiomyopathy: Four case histories and a commentary on anaesthetic management. Anaesth Intensive Care 1997;25:292-296 (Pubitemid 27296503)
88. Pirlet M, Baird M, Pryn S, et al. Low dose combined spinal-epidural anaesthesia for caesarean section in a patient with peripartum cardiomyopathy. Int J Obstet Anesth 2000;9:189-192 (Pubitemid 30447140)
89. Shnaider R, Efri T, Sjmuk P, et al. Combined spinal - epidural anaesthesia for cesarean section in a patient with peripartum dilated cardiomyopathy. Can J Anaesth 2001;48:681-683 (Pubitemid 32894303)
90. Kotekar N, Nagalakshmi NV, Chandrashekar. A rare case of peripartum cardiomyopathy posted for caesarian section. Indian J Anaesth 2007;51:60-64
91. Pryn A, Bryden F, Reeve W, et al. Cardiomyopathy in pregnancy and casesarean section: Four case reports. Int J Obstet Anesth 2007;16:68-73. (Pubitemid 44909448)
92. Dob DP, Yentis SM. Practical management of the parturient with congenital heart disease. Int J Obstet Anesth 2006;15:137-144
93. Demakis JG, Rahimtoola S, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation 1971;44:1053-1061
94. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276
95. Elkayam U, Akhter MW, Singh HS, et al. Pregnancy-associated cardiomyopathy: Clinical characteristics and a comparison between early and late presentation. Circulation 2005;111:2050-2055 (Pubitemid 40577899)
96. Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006;97:1765-1768 (Pubitemid 43817868)
97. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardidomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National INstitues of Health) workshop recommendations and review. JAMA 2000;283:1183-1188 (Pubitemid 30126607)
98. Bultmann BD, Klingel K, Nabauer M. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gyn 2005;193:363-365 (Pubitemid 41159528)
99. Kuhl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965-1970 (Pubitemid 41377415)
100. Ansari AA, Fett JD, Carraway RD, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002;23:289-312.
101. Melvin KR, Richarson PJ, Olsen EG, et al. Peripartum cardiomyopathy due to myocarditis. N Engl J Med 1982;307:731-734
102. Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease: An endomyocardial biopsy study. Br Heart J 1986;56:285-291 (Pubitemid 16011160)
103. Midei MG, DeMent SH, Feldman AM, et al. Peripartum myocarditis and cardiomyopathy. Circulation 1990;81:922-928
104. Rizeq MN, Rickenbacher PR, Fowler MB, et al. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 1994;74:474-477
105. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage HF. N Eng J Med 1996;335:1182-1189
106. Hayakawa Y, Chandra M, Miao W, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 2003;108:3036-3041 (Pubitemid 37553575)
107. Artlett CM, Smith JB, Jiminez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Eng J Med 1998;338:1186-1191 (Pubitemid 28180747)
108. Nelson JL. Microchimerism: Expanding new horizon in human health or incidental remnant of pregnancy? Lancet 2001;358:2011-2012
109. Hilfiker-Kleiner D, Kaminski K, Padewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:437-438 (Pubitemid 46206082)
110. Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007;50:2354-2355 (Pubitemid 350192108)
111. Aziz TM, Burgess MI, Aciadious NN, et al. Heart transplantation for peripartum cardiomyopathy: A report of three cases and a literature review. Cardiovasc Surg 1999;7:565-567 (Pubitemid 29349674)
112. Amos AM, Jaber WA, Russell DS. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006;152:509-513
113. Pulerwitz TC, Cappola TP, Felker GM, et al. Mortality in primary and secondary myocarditis. Am Heart J 2004;147:746-750
114. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006;368:687-693 (Pubitemid 44223695)
115. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clinic Proc 2005;80:1602-1606
116. Lampert MB, Weinert L, Hibbard J, et al. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 1997;176:189-195 (Pubitemid 127780770)
117. Sliwa K, Skudicky D, Bergemann A, et al. Peripartum cardiomyopathy: Analysis of clinical outcome, left ventricular function, plasma levels of cytokines, and Fas/Apo-1. J Am Coll Cardiol 2000;35:701-705 (Pubitemid 30167027)
118. Elkayam U, Padmini P, Tummala P, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001;344:1567-1571 (Pubitemid 32479908)
119. Habli M, O'Brien T, Nowack E, et al. Peripartum cardiomyopathy: Prognostic factors for long-term maternal outcome. Am J Obstet Gynecol 2008;199:415.e1-5
120. Faxon DP, Schwamm LH, Pasternak RC, et al. American Heart Association's Expert Panel on Disease Management. Circulation 2004;109:2651-2654
121. Hauptman PJ, Rich MW, Heidenreich PA, et al. The HF clinic: A consensus statement of the HF Society of America. J Cardiac Fail 2008;14:801-815
122. Yu DSF, Thompson DR, Lee DTF. Disease management programmes for older people with HF: Crucial characteristics which improve post-discharge outcomes. Eur Heart J 2006;27:596-612.
123. Roccaforte R, Demers C, Baldassare F, Teo KK, Yusuf S. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in HF patients. A meta-analysis. Eur J Heart Fail 2005;7:1133-1144 (Pubitemid 41721116)
124. Phillips CO, Singa RM, Rubin HR, Jaarsma T. Complexity of program and clinical outcomes of HF disease management incorporating specialist nurse-led HF clinics. A meta-regression analysis. Eur J Heart Fail 2005;7:333-341 (Pubitemid 40249525)
125. Gonseth J, Guallar-Castillon P, Banegas JR, Rodriguez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with HF: A systematic review and meta-analysis of published reports. Eur Heart J 2004;25:1570-1595 (Pubitemid 39209278)
126. Whellan DF, Hasselblad V, Peterson E, O'Connor CM, Schulman KA. Metaanalysis and review of HF disease management randomized controlled clinical trials. Am Heart J 2005;149:722-729 (Pubitemid 40501501)
127. McAlister FA, Stewart S, Ferrua S, McMurray JJJV. Multidisciplinary strategies for the management of HF patients at high risk for admission. J Am Coll Cardiol 2004;44:810-819
128. Ducharme A, Doyon O, White M, Rouleau JL, Brophy JM. Impact of care at a multidisciplinary congestive HF clinic: A randomized trial. CMAJ 2005;173:40-45 (Pubitemid 40980939)
129. Dunagan WC, Littenberg B, Ewald GA, et al. Randomized trial of a nurse-administered, telephone-based disease management program for patients with HF. J Cardiac Fail 2005;11:358-365 (Pubitemid 40799401)
130. Bruggink-André de la Porte PW, Lok DJA, van Veldhuisen DJ, et al. Added value of a physician-and-nurse-directed HF clinic: Results from the Deventer-Alkmaar HF study. Heart 2007;93:819-825
131. Del Sindaco D, Pulignano G, Minardi G, et al. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with HF. J Cardiovascular Med 2007;8:324-329
132. Cleland JGF, Louis AA, Rigby AS, Janssens U, Balk AHMM, on behalf of the TEN-HMS Investigators. Noninvasive home telemonitoring for patients with HF at high risk of recurrent admission and death. The Trans-European Network-Home-Care Management System (TEN-HMS) Study. J Am Coll Cardiol 2005;45:1654-1664 (Pubitemid 40704502)
133. Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with HF. Circulation 2004;110:3518-3526 (Pubitemid 39612565)
134. GESICA Investigators. Randomized trial of telephone intervention in chronic HF: DIAL trial. BMJ 2005;331:425-429
135. Jaarsma T, van der Wal MHL, Lesman-Leegte I, et al, for the Coordinating Study Evaluating Outcomes of Advising and Counseling in HF (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with HF. Arch Intern Med 2008;168:316-324 (Pubitemid 351281679)
136. Nguyen V, Ducharme A, White M, et al. Lack of long-term benefits of a 6-month HF disease management program. J Cardiac Fail 2007;13:287-293 (Pubitemid 46766638)
137. Houde S, Feldman DE, Pilote L, et al. Are there sex-related differences in specialized, multidisciplinary congestive HF clinics? Can J Cardiol 23:451-455
138. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: A systematic review of randomized trials. Arch Intern Med 2008;168:687-694 (Pubitemid 351563951)
139. Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive HF: A meta-analysis. JAMA 2004;291:1358-1367 (Pubitemid 38541651)
140. Gregory D, Kimmelstiel C, Perry K, Parikh A, Konstam V, Konstam MA. Hospital cost effect of a HF disease management program: The specialized primary and networked care in HF (SPAN-CHF) trial. Am Heart J 2006;151:1013-1018
141. Hebert PL, Sisk JE, Wang JJ, et al. Cost-effectiveness of nurse-led disease management for HF in an ethnically diverse urban community. Ann Intern Med 2008;149:540-548
142. Turner DA, Paul S, Stone MA, Juarez-Garcia A, Squire I, Khunti K. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and HF in primary care. Heart 2008;94:1601-1606
143. Whellan DJ, Reed SD, Liao L, Gould SD, O'Connor CM, Schulman KA. Financial implications of a model HF disease management program for providers, hospital, healthcare systems, and payer perspectives. Am J Cardiol 2007;99:256-260 (Pubitemid 46072762)
144. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Committee on Quality of Health Care in America. Washington: National Academy Press, 2001.
145. Fishman PA, Hornbrook MC, Meenan RT, Goodman MJ. Opportunities and challenges for measuring cost, quality, and clinical effectiveness in health care. Med Care Res Rev 2004;61;124S-143S.
146. Rubin HR, Pronovost P, Diette GB. The advantages and disadvantages of process-based measures of health care quality. Int J Qual Health Care 2001;13:469-474 (Pubitemid 33133921)
147. Mant J. Process versus outcome indicators in the assessment of quality of health care. Int J Qual Health Care 2001;13:475-480 (Pubitemid 33133922)
148. Campbell SM, Braspenning J, Hutchinson A, Marshall MN. Research methods used in developing and applying quality indicators in primary care. BMJ 2003;326:816-819 (Pubitemid 35463394)
149. Donabedian A. Quality assessment and assurance: Unity of purpose, diversity of means. Inquiry 1988;25:173-192
150. Tu JV, Nardi L, Fang J, Liu J, Khalid L, Johansen H. National trends in rates of death and hospital admissions related to acute myocardial infarction, HF and stroke, 1994-2004. CMAJ 2009;180:1304-1309
151. Litaker JR, Chou JY. Patterns of pharmacologic treatment of congestive HF in elderly nursing home residents and related issues: A review of the literature. Clin Ther 2003;25:1918-1935
152. Rangaswamy C, Finn JI, Koelling TM. Angiotensin-converting enzyme inhibitor use in elderly patients hospitalized with HF and left ventricular systolic dysfunction. Cardiology 2005;103:17-23. (Pubitemid 39541241)
153. Shibata MC, Soneff CM, Tsuyuki RT. Utilization of evidence-based therapies for HF in the institutionalized elderly. Eur J Heart Fail 2005;7:1122-1125
154. De Groote P, Isnard R, Assyag P, et al. Is the gap between guidelines and clinical practice in HF treatment being filled? Insights from the IMPACT RECO study. Eur J Heart Fail 2007;9:1205-1211 (Pubitemid 350153640)
155. Cleland JGF, Cohen-Solal A, Aguilar JC, et al. Management of HF in primary care (the IMPROVEMENT of HF Programme): An international survey. Lancet 2002;360:1631-1639 (Pubitemid 35379734)
156. Goodlin SJ. Palliative care in congestive HF. J Am Coll Cardiol 2009;54:386-396
157. Lee DS, Tran C, Flintoft V, Grant FC, Liu PP, Tu JV; Canadian Cardiovascular Outcomes Research Team/Canadian Cardiovascular Society HF Quality Indicator Panel. CCORT/CCS quality indicators for congestive HF care. Can J Cardiol 2003;19:357-364 (Pubitemid 36603500)
158. Bonow RO, Masoudi FA, Rumsfeld JS, et al; American College of Cardiology; American Heart Association Task Force on Performance Measures. ACC/AHA classification of care metrics: Performance measures and quality metrics: A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol 2008;52:2113-2117
159. Joint Commission on Accreditation of Healthcare Organizations. Specifications Manual for National Hospital Quality Measures. 2006.
160. Heidenreich PA, Fonarow GC. Quality indicators for the care of HF in vulnerable elders. J Am Geriatr Soc 2007;55(Suppl 2):S340-6.
161. Heidenreich P. Improving HF care with a reminder attached to the echocardiography. Am J Med 2008;121:853-854
162. Ansari M, Shlipak MG, Heidenreich PA, et al. Improving guideline adherence: A randomized trial evaluating strategies to increase beta-blocker use in HF. Circulation 2003;107:2799-2804 (Pubitemid 36705989)
163. Frijling BD, Lobo CM, Hulscher ME, et al. Intensive support to improve clinical decision making in cardiovascular care: A randomised controlled trial in general practice. Qual Saf Health Care 2003;12:181-187 (Pubitemid 36723944)
164. Thilly N, Briancon S, Juilliere Y, Dufay E, Zannad F. Improving ACE inhibitor use in patients hospitalized with systolic HF: A cluster randomized controlled trial of clinical practice guideline development and use. J Eval Clin Pract 2003;9:373-382 (Pubitemid 36999143)
165. Tierney WM, Overhage JM, Murray MD, et al. Effects of computerized guidelines for managing heart disease in primary care. J Gen Intern Med 2003;18:967-976
166. Feldman PH, Peng TR, Murtaugh CM, et al. A randomized intervention to improve HF outcomes in community-based home health care. Home Health Care Serv Q 2004;23:1-23.
167. Guadagnoli E, Normand SL, DiSalvo TG, Palmer RH, McNeil BJ. Effects of treatment recommendations and specialist intervention on care provided by primary care physicians to patients with myocardial infarction or HF. Am J Med 2004;117:371-379 (Pubitemid 39369541)
168. LaPointe NM, DeLong ER, Chen A, et al. Multifaceted intervention to promote beta-blocker use in HF. Am Heart J 2006;151:992-998
169. Majumdar SR, Tsuyuki RT, McAlister FA. Impact of opinion leader- endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: A randomized controlled trial. Am Heart J 2007;153:22.e1-8
170. Gardetto NJ, Greaney K, Arai L, et al. Critical pathway for the management of acute HF at the Veterans Affairs San Diego Healthcare System: Transforming performance measures into cardiac care. Crit Pathw Cardiol 2008;7:153-172
171. Peters-Klimm F, Müller-Tasch T, Remppis A, Szecsenyi J, Schellberg D. Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice - results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. J Eval Clin Pract 2008;14:823-829
172. Greenhalgh T, Robert G, MacFarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: Systematic review and recommendations. Milbank Q 2004;82:581-629. (Pubitemid 40143100)
173. Mollon B, Chong J Jr, Holbrook AM, Sung M, Thabane L, Foster G. Features predicting the success of computerized decision support for prescribing: A systematic review of randomized controlled trials. BMC Med Inform Decis Mak 2009;9:11.
174. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. Does telling people what they have been doing change what they do? A systematic review of the effects of audit and feedback. Qual Saf Health Care 2006;15;433-436 (Pubitemid 46025156)
175. Werner RM, Bradlow ET. Relationship between Medicare's hospital compare performance measures and mortality rates. JAMA 2006;296:2694-2702 (Pubitemid 44920181)
176. Albert NM, Fonarow GC, Abraham WT, et al. Predictors of delivery of hospital-based heart failure patient education: A report from OPTIMIZE-HF. J Card Fail 2007;13:189-198
177. Fonarow GC, Abraham WT, Albert NM, et al; OPTIMIZE-HF Investigators and Hospitals. Influence of a performance- improvement initiative on quality of care for patients hospitalized with HF: Results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007;167:1493-1502 (Pubitemid 47134697)
178. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with HF. JAMA 2007;297:61-70. (Pubitemid 46041727)
179. Fonarow GC, Yancy CW, Albert NM, et al. Improving the use of evidence-based heart failure therapies in the outpatient setting: The IMPROVE HF performance improvement registry. Am Heart J 2007;154:12-38.
180. Yancy CW, Fonarow GC, Albert NM, et al. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF. Am Heart J 2009;157:754-762
181. Fonarow GC, Corday E; ADHERE Scientific Advisory Committee. Overview of acutely decompensated congestive HF (ADHF): A report from the ADHERE registry. Heart Fail Rev 2004;9:179-185
182. Yancy CW, Fonarow GC; ADHERE Scientific Advisory Committee. Quality of care and outcomes in acute decompensated HF: The ADHERE Registry. Curr Heart Fail Rep 2004;1:121-128
183. Fonarow GC, Yancy CW, Heywood JT; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Adherence to HF quality-of-care indicators in US hospitals: Analysis of the ADHERE Registry. Arch Intern Med 2005;165:1469-1477
184. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW; ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for HF hospitalizations, 2002 to 2004: Findings from Acute Decompensated HF National Registry (ADHERE). Am Heart J 2007;153:1021-1028 (Pubitemid 46809844)
185. Filardo G, Nicewander D, Herrin J, et al. A hospital-randomized controlled trial of a formal quality improvement educational program in rural and small community Texas hospitals: One year results. Int J Qual Health Care 2009;21:225-232
186. Tu J, Donovan LR, Lee DS, et al. Effectiveness of public report cards for improving the quality of cardiac care: The EFFECT study: A randomized trial. JAMA 2009;302:2330-2337
187. Fonarow GC, Peterson ED. HF performance measures and outcomes: Real or illusory gains. JAMA 2009;302:792-794
188. Arnold JMO, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on HF 2006: Diagnosis and management. Can J Cardiol 2006;22:23-45. (Pubitemid 43299308)
189. Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on HF update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007;23:21-45. (Pubitemid 46403407)
190. Arnold JMO, Howlett JG, Ducharme A, et al. Canadian Cardiovascular Society Consensus Conference guidelines on HF - 2008 update: Best practices for the transition of care of HF patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol 2008;24:21-40. (Pubitemid 351385400)
191. Perrin B. Effective use and misuse of performance measurement. Am J Eval 1998;19:367-379 (Pubitemid 128183953)
192. McDonald KM, Sundaram V, Bravata DM, et al. Care coordination. In: Shojania KG, McDonald KM, Wachter RM, Owens DK, eds. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies. Technical Review 9 (Prepared by the Stanford University-UCSF Evidence-based Practice Center under contract 290-02-0017). AHRQ Publication No 04(07)-0051-57 Rockville: Agency for Healthcare Research and Quality, 2007.
193. Peikes D, Chen A, Schore J, Brown R. Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries. JAMA 2009;301:603-618
194. Niessen LW, Grijseels EWM, Rutten FFH. The evidence-based approach to health policy and heath care delivery. Soc Sci Med 2000;51:859-869
195. Klazinga N. Re-engineering trust: The adoption and adaption of four models for external quality assurance of health care services in western European health care systems. Int J Qual Health Care 2000;12:183-189 (Pubitemid 30429698)
196. Burge FI, Bower K, Putnam W, Cox JL. Quality indicators for cardiovascular primary care. Can J Cardiol 2007;23:383-388 (Pubitemid 46901896)